At ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
ASCO25, Prof. Yilong Wu shared key insights on the latest advances in lung cancer treatment.
Prof. Olaf Penack: Standardized GVHD Management in Europe and Future Strategies | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note: The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of…
Prof. Anna Sureda, President of EBMT, on China-Europe Collaboration and the Future of Cellular Therapy | 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy
Editor’s Note:The 2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy was recently held successfully in Guangzhou. The conference was co-hosted by the Hematology Branch of the…
Professor Shun Lu: High Efficacy and Low Toxicity—SHR-A1811 Opens a New Era of ADC Therapy for HER2-Mutant NSCLC
At the 2025 Annual Meeting of the American Association for Cancer Research (AACR), the China-developed HER2-directed antibody-drug conjugate (ADC) Trastuzumab rezetecan(SHR-A1811) made a striking appearance with new data from the HORIZON-Lung study: an objective response rate (ORR) of 74.5%, a median progression-free survival (PFS) of 11.5 months, and an interstitial lung disease (ILD) incidence of just 8.5%—setting new records among global studies in this space.
An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China
An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China, the International Workshop on Cell Therapy of Blood Diseases hosted by the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science (IHCAMS) and supported by the Ministry of Science and Technology of the People's Republic of China will be grandly held.
50 Years of Hematopoietic Stem Cell Transplantation: Xiaojun Huang on China’s Transformative Journey
From April 11 to 12, 2025, the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) held its annual academic meeting in Qingdao, Shandong…
Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang
We are thrilled to share an exclusive presentation by Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences. In this engaging session, Professor Wang delves into the groundbreaking findings of the Phase 3 Commodore study, recently published in Leukemia. This study provides critical new evidence on the efficacy of gilteritinib, a FLT3-inhibiting TKI, in treating relapsed or refractory FLT3-mutated acute myeloid leukemia (AML) among predominantly Asian patients.
Transforming Cancer Care: Insights from Professor Jun Zhou
Professor Jun Zhou from Shanghai GoBroad Cancer Hospital and China Pharmaceutical University discusses the pivotal findings of the CheckMate 649 study. This landmark trial has redefined the first-line treatment for advanced gastric cancer, showcasing the power of immunotherapy combined with chemotherapy.
Prof. Jie Wang on Integrating Targeted Therapy, Immunotherapy, and ADCs in Lung Cancer Management | Tianfu Oncology Conference
At the recent 7th Tianfu Oncology Conference, Professor Jie Wang from the Cancer Hospital, Chinese Academy of Medical Sciences, delivered a keynote presentation titled “Integrative Strategies in Lung Cancer: Targeted Therapy, Immunotherapy, and ADC Management.”
ADC Research Led by Sun Yat-sen University Cancer Center May Influence Future Treatment Guidelines
With advances in technology and growing clinical experience, China’s development of antibody-drug conjugates (ADCs) has evolved from following international trends to driving innovation independently. A recent example is the phase I clinical trial of YL201—the world’s first B7-H3-targeted ADC for advanced solid tumors—led by Professors Li Zhang and Hongyun Zhao from Sun Yat-sen University Cancer Center. The results were published in Nature Medicine, one of the most respected medical journals worldwide, marking a new step in global recognition for domestically developed therapies.
